Sector Wrap: Pharmaceuticals, Financials, REITs

It was announced that Ratiopharm had accepted a bid from Teva for about $5 billion. The combined company will have a strong presence in Europe as Ratiopharm is the #2 generic drug maker in Germany. Despite the positive news
NASDAQ:IBB March 18, 2010 2:51pm

Get Free Updates

Join over 50,000 investors who get the latest news from!

Most Popular

From Our Partners

Explore More from

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again! respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories